Literature DB >> 9616141

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.

M Maier-Redelsperger1, M de Montalembert, A Flahault, M G Neonato, R Ducrocq, M P Masson, R Girot, J Elion.   

Abstract

We have studied the cellular and molecular responses to long-term hydroxyurea (HU) treatment in 29 severely affected young patients with sickle cell disease (mean age, 10.9 +/- 4.1 years). Patients received HU at 20 mg/kg/d on 4 consecutive days per week initially, with a monthly escalated dose avoiding marrow-toxicity (mean steady-state dose, 34.2 +/- 4.6 mg/kg/d) for 12 to 36 months (mean duration, 22 months). The studied parameters were hemoglobin F (HbF), F reticulocytes (F retics), F cells, the amount of HbF per F cell (F/F cell), polymer tendency at 40% and 70% oxygen saturation, and hemolysis. Initial HbF (Fi) was dispersed (from 0.85% to 13.9%). HbF increased in all patients but 1. HbF at maximal response (Fmax) reached a sustained level varying from a 1.5-fold to a 16-fold Fi after a variable delay (6 to 24 months). Fmax was not related to HU dosage, but triangle upF (Fmax - Fi) was strongly correlated to triangle upMCV (MCVmax - MCVi). HbF increase resulted from the increase of both F cells and F/F cell. In this rather short series, Fi and Fmax were not significantly associated with age, gender, or beta-globin haplotype. Neither Fmax nor triangle upF was related to bone marrow reserve, as measured by baseline reticulocyte or neutrophil counts. However, Fmax was highly dependent on Fi. When patients are individualized into three groups according to Fmax (group 1, Fmax >20% [12 patients]; group 2, 10% < Fmax < 20% [11 patients]; group 3, Fmax <10% [5 patients]), Fi is significantly different between groups, being the highest in group 1. In addition, the best responders (group 1) were significantly different from patients in the two other groups with higher levels of total hemoglobin, decreased bilirubin, and decreased polymer tendency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616141

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.

Authors:  Ajay Perumbeti; Tomoyasu Higashimoto; Fabrizia Urbinati; Robert Franco; Herbert J Meiselman; David Witte; Punam Malik
Journal:  Blood       Date:  2009-05-27       Impact factor: 22.113

2.  Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques (Macaca fasicularis).

Authors:  Mila C Kundu; Liz R Gore; Sean Maguire; Aidan G Gilmartin
Journal:  Comp Med       Date:  2018-08-09       Impact factor: 0.982

3.  Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Authors:  Arlene Smaldone; Sally Findley; Suzanne Bakken; L Adriana Matiz; Susan L Rosenthal; Haomiao Jia; Sergio Matos; Deepa Manwani; Nancy S Green
Journal:  Contemp Clin Trials       Date:  2016-06-17       Impact factor: 2.226

4.  Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.

Authors:  Steffen E Meiler; Marlene Wade; Ferdane Kutlar; Shobha D Yerigenahally; Yongjun Xue; Laure A Moutouh-de Parseval; Laura G Corral; Paul S Swerdlow; Abdullah Kutlar
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

Review 5.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

6.  Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.

Authors:  M de Montalembert; P Bégué; F Bernaudin; I Thuret; D Bachir; M Micheau
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

7.  Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.

Authors:  G F Atweh; M Sutton; I Nassif; V Boosalis; G J Dover; S Wallenstein; E Wright; L McMahon; G Stamatoyannopoulos; D V Faller; S P Perrine
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

8.  Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.

Authors:  Jane A Little; Kristine Partovi Hauser; Sabrina E Martyr; Amy Harris; Irina Maric; Claudia R Morris; Jung H Suh; James Taylor; Oswaldo Castro; Roberto Machado; Gregory Kato; Mark T Gladwin
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

9.  Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.

Authors:  Eugene Khandros; Peng Huang; Scott A Peslak; Malini Sharma; Osheiza Abdulmalik; Belinda M Giardine; Zhe Zhang; Cheryl A Keller; Ross C Hardison; Gerd A Blobel
Journal:  Blood       Date:  2020-05-28       Impact factor: 22.113

10.  Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.

Authors:  Antara Banerjee; Sudipa Basu Chakrabarty; Susanta Roy Karmakar; Amit Chakrabarty; Surjyo Jyoti Biswas; Saiful Haque; Debarsi Das; Saili Paul; Biswapati Mandal; Boujedaini Naoual; Philippe Belon; Anisur Rahman Khuda-Bukhsh
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.